XJPX4596
Market cap18mUSD
Dec 30, Last price
53.00JPY
1D
3.92%
1Q
-15.87%
Jan 2017
-94.92%
IPO
-94.67%
Name
Kubota Pharmaceutical Holdings Co Ltd
Chart & Performance
P/E
—
P/S
73.91
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
40m
+383.24%
Net income
-1.49b
L-26.11%
CFO
-1.34b
L-36.02%
Profile
Kubota Pharmaceutical Holdings Co., Ltd. develops portfolio of drugs and devices worldwide. Its product pipeline comprises emixustat hydrochloride, which is in Phase III clinical stage used for the treatment of stargardt disease, and Phase II clinical stage used for the treatment of proliferative diabetic retinopathy. The company is also developing remote retinal monitoring device patient-based ophthalmology suite, that includes home-based miniature and NASA high-res version optical coherence tomography devices; and wearable device for myopia control. The company was founded in 2002 and is based in Tokyo, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 39,887 383.24% | 8,254 | |||
Cost of revenue | 887,722 | 2,119,980 | |||
Unusual Expense (Income) | |||||
NOPBT | (847,835) | (2,111,726) | |||
NOPBT Margin | |||||
Operating Taxes | (4,042,363) | ||||
Tax Rate | |||||
NOPAT | (847,835) | 1,930,637 | |||
Net income | (1,489,602) -26.11% | (2,015,906) -22.95% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 148,368 | 1,514,903 | |||
BB yield | -3.34% | -26.74% | |||
| Debt | |||||
Debt current | 55,000 | 233,622 | |||
Long-term debt | 229,000 | 257,961 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (2,500,000) | (3,557,386) | |||
| Cash flow | |||||
Cash from operating activities | (1,335,000) | (2,086,695) | |||
CAPEX | (66,000) | (57,976) | |||
Cash from investing activities | (45,000) | 505,159 | |||
Cash from financing activities | 96,000 | 1,446,787 | |||
FCF | (767,325) | 1,966,111 | |||
| Balance | |||||
Cash | 2,767,000 | 4,048,969 | |||
Long term investments | 17,000 | ||||
Excess cash | 2,782,006 | 4,048,556 | |||
Stockholders' equity | (24,991,000) | (22,113,948) | |||
Invested Capital | 27,780,000 | 26,406,498 | |||
ROIC | 7.43% | ||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | 55,594 | 49,266 | |||
Price | 80.00 -30.43% | 115.00 -22.82% | |||
Market cap | 4,447,520 -21.50% | 5,665,645 -16.50% | |||
EV | 1,947,520 | 3,571,629 | |||
EBITDA | (760,675) | (2,052,752) | |||
EV/EBITDA | |||||
Interest | 11,563 | ||||
Interest/NOPBT | |||||